Epidermal Growth Factor Receptor Inhibition With Erlotinib in Liver: Dose De-Escalation Pilot Trial as an Initial Step in a Chemoprevention Strategy

Author:

Tanabe Kenneth K.,Zahrieh David,Strand Carrie A.,Hoshida Yujin,Flotte Thomas J.,Della’Zanna Gary,Umar Asad,Chavin Kenneth D.,Cleary Sean,Kubota Naoto,Llovet Josep M.,Patel Tushar,Siegel Christopher,Limburg Paul J.

Funder

NIH

Samuel Waxman Cancer Research Foundation

Fundacion Cientifica de la Asociacion Espaoola Contra el Cancer

Publisher

Elsevier BV

Reference40 articles.

1. Cancer statistics, 2021;Siegel;CA Cancer J Clin,2021

2. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma;Llovet;Nat Cancer,2022

3. Risk factors, pathogenesis, and strategies for hepatocellular carcinoma prevention: emphasis on secondary prevention and its Translational challenges;Li;J Clin Med,2020

4. Cellular mechanisms of liver fibrosis;Acharya;Front Pharmacol,2021

5. Targeting oxidative stress for the treatment of liver fibrosis;Luangmonkong;Rev Physiol Biochem Pharmacol,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3